- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03131336
PeproStat as a Topical Agent Used to Stop Bleeding in Patients Undergoing Surgery
A Controlled, Randomized, Multi-centre, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeproStat in Intraoperative Surgical Haemostasis
Study Overview
Detailed Description
PeproStat is a new class of topical haemostatic agent composed of recombinant human albumin (rHA) conjugated with fibrinogen-binding peptides. The conjugate polymerises fibrinogen into a fibrin-like clot without the need for thrombin.
PeproStat is formulated in a liquid, and is soaked into a haemostatic gelatin sponge in the operating theatre, and applied directly to the site of bleeding. The gelatin sponge (Spongostan ) is an approved "passive" haemostat i.e., PeproStat is an adjunct to a passive haemostat.
The study is designed in a 2:1 randomization (verum:placebo) to investigate the efficacy in terms of Time to hemostasis, mean (mTTH) at the primary target bleed site (TBS), measured in minutes (min) from the start of treatment application (TxStart) at the TBS to the achievement of hemostasis at that site or to the end of the 10-minute assessment period if hemostasis has not yet been achieved.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sarajevo, Bosnia and Herzegovina, 71000
- University Clinical Hospital, Bolnicka 25
-
-
-
-
-
Zagreb, Croatia, 10000
- University Clinical Hospital Centre "Sestre Milosrdnice", Vinogradska cesta 29
-
-
-
-
-
Gdańsk, Poland, 80-952
- Klinika Neurochirurgii Gdanskie Centrum Kliniczne, ul. Dębinki 7
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical centre of Serbia, Clinic for vascular and endovascular surgery, Koste Todorovica Street 8
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrookes Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: At screening and baseline:
- Subject is undergoing a planned open liver/soft tissue surgery, vascular surgery or spine surgery.
- Subjects are able and willing to provide written informed consent to participate in this study.
- Adult males and females ≥18 years of age at screening.
- Willing and able to comply with all protocol requirements including follow-up assessments.
- Male subjects must be willing and able to use adequate contraception from enrollment through to the 30 day follow-up visit.
Women of childbearing potential (WCBP)C have to use highly effective methods of contraception from enrollment through to the 30 day follow-up visit.
Intraoperative:
- The subject presents an identified target bleeding site with mild or moderate bleeding, which conventional surgical techniques are insufficient to control or are inappropriate and would otherwise be a candidate for standard haemostats.
- The subject presents no intraoperative complications, other than bleeding, that may interfere with study assessments as judged by the Investigator.
- The subject presents no contaminated areas of the body, signs of infection or abscess development.
- Total target bleeding site surface area of ≤ 70 cm2, defined within one or two TBSs.
Exclusion Criteria:
- Subject is undergoing emergency surgical procedure.
Use of study treatment and sponge in
- Closure of skin incisions as the sponge may interfere with the healing of skin edges.
- Intravascular compartments because of the risk of embolization following sponge application.
- Recipient of an organ transplant.
Haematologic, biochemistry and coagulation panel thresholds at screening:
- Haemoglobin ≤ 9.0 g/dL.
- Platelet count ≤100,000/mm3 (≤ 100 x 109/L).
- International Normalized Ratio (INR) > 2.0 or activated Partial Thromboplastin Time (aPTT) ratio > 2.0.
- Fibrinogen level < 1.5 g/L.
- Aspartate Aminotransferase (AST) or Alanine aminotransferase (ALT) ≥ 3 times the upper limit normal range, except for subjects undergoing liver resection surgery where there is no upper limit for these analytes due to the nature of their disease.
- Severe renal failure.
- Any other disease or condition that may affect normal blood clotting, for example thrombocytopenia, as judged by the Investigator.
- A known history of anaphylaxis or allergic reaction to human albumin, PEGylated proteins, yeast or moulds, porcine products or other components in the study medication or sponge.
- Participation in another investigational drug or device research study within 30 days before and after enrolment in the current study.
- Current known or suspected alcohol and/or drug abuse or dependence at the time of screening.
- Any concurrent medical, surgical, or psychiatric condition that may, in the Investigator's opinion, affect the subject's willingness or ability to meet all study requirements during the study duration.
- Known HIV, Hepatitis B virus or Hepatitis C Virus infection.
- During the surgery, subject presents severe bleeding where use of a topical haemostat would be inappropriate.
Anti-platelets/oral anticoagulants treatment:
- Soft tissue/liver and neurosurgery: Subject is taking anti-platelet agents or oral anticoagulants within 7 days of surgery
- Vascular surgery: Subject is taking dual anti-platelet treatment or oral anticoagulants within 7 days of surgery. One anti-platelet agent is allowed perioperatively.
Heparin treatment:
c. Soft tissue/liver and neurosurgery only: Subject is receiving therapeutic doses of heparin perioperatively. Only prophylactic Low Molecular Weight Heparin is allowed.
- Pregnant or breast-feeding subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PeproStat
PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
|
solution for local application
Other Names:
|
Placebo Comparator: Saline
Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
|
solution for local application
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in time to hemostasis in minutes when using verum vs placebo
Time Frame: 10 minutes after application
|
Efficacy in terms of Time to hemostasis, mean (mTTH) at the primary target bleed site (TBS),measured in minutes from the start of treatment application (TxStart) at the TBS to the achievement of haemostasis at that site or to the end of the 10-minute assessment period if haemostasis has not yet been achieved.
|
10 minutes after application
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects achieving hemostasis at 1 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics
Time Frame: 1 minute after start of treatment
|
Percentage of subjects achieving haemostasis within 1 minute from application of treatment
|
1 minute after start of treatment
|
Percentage of subjects achieving hemostasis at 2 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics
Time Frame: 2 minutes after start of treatment
|
Percentage of subjects achieving haemostasis within 2 minutes from application of treatment
|
2 minutes after start of treatment
|
Percentage of subjects achieving hemostasis at 3 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics
Time Frame: 3 minutes after start of treatment
|
Percentage of subjects achieving haemostasis within 3 minutes from application of treatment
|
3 minutes after start of treatment
|
Percentage of subjects achieving hemostasis at 5 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics
Time Frame: 5 minutes after start of treatment
|
Percentage of subjects achieving haemostasis within 5 minutes from application of treatment
|
5 minutes after start of treatment
|
Percentage of subjects achieving hemostasis at 7 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics
Time Frame: 7 minutes after start of treatment
|
Percentage of subjects achieving haemostasis within 7 minutes from application of treatment
|
7 minutes after start of treatment
|
Percentage of subjects achieving hemostasis at 10 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics
Time Frame: 10 minutes after start of treatment
|
Percentage of subjects achieving haemostasis within 10 minutes from application of treatment
|
10 minutes after start of treatment
|
Median time to hemostasis in minutes from TxStart to the achievement of hemostasis or to the end of the 10-minute assessment period if hemostasis has not yet been achieved
Time Frame: 10 minutes after start of treatment
|
Median time for haemostasis to be achieved
|
10 minutes after start of treatment
|
Number/rate of subjects who do not achieve hemostasis within 10 min
Time Frame: 10 minutes after start of treatment
|
Number/rate of subjects who do not achieve hemostasis within 10 min
|
10 minutes after start of treatment
|
Number of sponges applied at Target Bleeding Site (TBS)
Time Frame: Counted on Day of surgery
|
Number of sponges used at TBS, 1 or 2
|
Counted on Day of surgery
|
Dose of PeproStat determined by number and size (if cut to size) of PeproStat soaked sponges applied at TBS
Time Frame: Measured on day of surgery
|
Dose of PeproStat determined by number and size (if cut to size) of PeproStat soaked sponges applied at TBS
|
Measured on day of surgery
|
Number/rate of treatment failures
Time Frame: 10 minutes after start of treatment
|
Number of participants not achieving haemostasis within 10 minutes at primary, secondary or both TBS's
|
10 minutes after start of treatment
|
Use of alternative haemostatic agents at the TBS
Time Frame: Documented on the day of surgery
|
Number of participants requiring use of other haemostats at the TBS
|
Documented on the day of surgery
|
Investigator assessment of efficacy to obtain haemostasis
Time Frame: Documented on the day of surgery
|
Investigator's assessment of the efficacy of the treatment with a score of 1-5, where 5 is very effective
|
Documented on the day of surgery
|
Investigator assessment ease of use of study treatment
Time Frame: Documented on the day of surgery
|
Investigator assessment ease of use of study treatment with a score of 1-5, where 5 is very effective
|
Documented on the day of surgery
|
Adverse Events
Time Frame: Measured from the point of consent to Day 30
|
Number of Adverse Events (AEs) including adverse events of special interest: Bleeding at the TBS after 10-minute assessment period during or after surgery (if re-operation is required) and transfusion requirement
|
Measured from the point of consent to Day 30
|
Heparin usage
Time Frame: Measured from the point of consent to Day 30
|
Number of participants with Heparin usage
|
Measured from the point of consent to Day 30
|
Antiplatelet usage
Time Frame: Measured from the point of consent to Day 30
|
Number of participants with Antiplatelet usage
|
Measured from the point of consent to Day 30
|
Laboratory safety parameters
Time Frame: Measured at Day 5
|
Changes in Laboratory safety parameters at day 5 vs. screening
|
Measured at Day 5
|
Laboratory safety parameters
Time Frame: Measured at screening, Day 30
|
Laboratory safety parameters at day 30 vs. screening
|
Measured at screening, Day 30
|
Immunogenicity testing
Time Frame: Measured at screening and Day 30
|
Immunogenicity testing
|
Measured at screening and Day 30
|
Vital signs
Time Frame: Measured before surgery vs. screening
|
Changes in vital signs
|
Measured before surgery vs. screening
|
Vital signs
Time Frame: Measured during surgery (before treatment) vs. screening
|
Changes in vital signs
|
Measured during surgery (before treatment) vs. screening
|
Vital signs
Time Frame: Measured during surgery (15 minutes after treatment) vs. screening
|
Changes in vital signs
|
Measured during surgery (15 minutes after treatment) vs. screening
|
Vital signs
Time Frame: Measured at 4 hours after surgery vs. screening
|
Changes in vital signs
|
Measured at 4 hours after surgery vs. screening
|
Vital signs
Time Frame: Measured at 8 hours after surgery vs. screening
|
Changes in vital signs
|
Measured at 8 hours after surgery vs. screening
|
Vital signs
Time Frame: Measured at 16 hours after surgery vs. screening
|
Changes in vital signs
|
Measured at 16 hours after surgery vs. screening
|
12-lead electrocardiogram
Time Frame: measured at Day 5
|
Abnormalities in 12-lead electrocardiogram
|
measured at Day 5
|
12-lead electrocardiogram
Time Frame: measured at Day 30 (if medically indicated)
|
Abnormalities in 12-lead electrocardiogram
|
measured at Day 30 (if medically indicated)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Hayes, Addenbrookes NHS Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HX-02-PEP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
Ethicon, Inc.Guangzhou Bioseal Biotechnology Co., Ltd.Completed
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Wake Forest University Health SciencesCompletedBleeding ComplicationUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
Clinical Trials on PeproStat
-
Haemostatix LtdCompleted